DUBLIN–(BUSINESS WIRE)–The “Coronavirus Disease 2019 (COVID-19) Impact on Immunology Trials – July 2020” report has been added to ResearchAndMarkets.com’s offering.

Since the beginning of March 2020, clinical trial operations were most disrupted as a result of the COVID-19 pandemic. This report summarizes the impact on immunology patient, clinical trial logistics, and key opinion leader (KOL) insights on the long-term impact of the pandemic.

Report Scope

• Global overview of changes to clinical practice and clinical trial logistics in H1 2020 in 8MM (US, 5EU, Japan, Canada)
• Summary of primary research with Immunology Key Opinion Leaders
• Forward-looking perspective of potential long-term ramifications of COVID pandemic

Reasons to Buy

• Understand the impact of COVID-19 on immunology clinical trials
• Obtain a snapshot of the regulatory guidance issued by the US FDA, EMA, and Health Canada
• Understand the impact of COVID on continuity of care for immunology patients
• Understand the impact of COVID on clinical trial logistics (including trial recruitment, trial conduct, and supply chain)
• Understand the potential long-term impact of COVID on clinical trial conduct and clinical practice

Key Topics Covered

1 Immunology Trials Disrupted

(Read more…)

1.1 Overview of Immunology Trials Disrupted

1.2 Regulatory Guidance Across the 8MM

2 KOL Insights: Continuity of Care

3 KOL Insights: Trial Logistics

3.1 Recruitment

3.2 Conduct in Isolation

3.3 Supply Chain

4 KOL Insights: Trials Looking Forward

4.1 Clinical Trials Disrupted Due to COVID

4.2 Immunology Clinical Trials Resumed

5 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/3zkta8.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Coronavirus Disease 2019 (COVID-19) Impact on Immunology Trials – July 2020” report has been added to ResearchAndMarkets.com’s offering.

Since the beginning of March 2020, clinical trial operations were most disrupted as a result of the COVID-19 pandemic. This report summarizes the impact on immunology patient, clinical trial logistics, and key opinion leader (KOL) insights on the long-term impact of the pandemic.

Report Scope

• Global overview of changes to clinical practice and clinical trial logistics in H1 2020 in 8MM (US, 5EU, Japan, Canada)
• Summary of primary research with Immunology Key Opinion Leaders
• Forward-looking perspective of potential long-term ramifications of COVID pandemic

Reasons to Buy

• Understand the impact of COVID-19 on immunology clinical trials
• Obtain a snapshot of the regulatory guidance issued by the US FDA, EMA, and Health Canada
• Understand the impact of COVID on continuity of care for immunology patients
• Understand the impact of COVID on clinical trial logistics (including trial recruitment, trial conduct, and supply chain)
• Understand the potential long-term impact of COVID on clinical trial conduct and clinical practice

Key Topics Covered

1 Immunology Trials Disrupted

(Read more…)

1.1 Overview of Immunology Trials Disrupted

1.2 Regulatory Guidance Across the 8MM

2 KOL Insights: Continuity of Care

3 KOL Insights: Trial Logistics

3.1 Recruitment

3.2 Conduct in Isolation

3.3 Supply Chain

4 KOL Insights: Trials Looking Forward

4.1 Clinical Trials Disrupted Due to COVID

4.2 Immunology Clinical Trials Resumed

5 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/3zkta8.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900